International Journal of Cancer Management

Published by: Kowsar
Crossmark

Varying miR-193b-3p Expression Patterns in Breast Cancer Cell Lines Indicates Its Potential for Cancer Management Strategies

Zahra Sadat Hashemi 1 , Mehdi Forouzandeh Moghadam 2 and Esmaeil Sadroddiny 1 , *
Authors Information
1 Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Article information
  • International Journal of Cancer Management: August 2018, 11 (8); e63540
  • Published Online: August 15, 2018
  • Article Type: Research Article
  • Received: November 1, 2017
  • Revised: December 5, 2017
  • Accepted: December 10, 2017
  • DOI: 10.5812/ijcm.63540

How to Cite: Hashemi Z S, Forouzandeh Moghadam M, Sadroddiny E. Varying miR-193b-3p Expression Patterns in Breast Cancer Cell Lines Indicates Its Potential for Cancer Management Strategies, Int J Cancer Manag. 2018 ; 11(8):e63540. doi: 10.5812/ijcm.63540.

Abstract
Copyright © 2018, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Al Zaabi AA. Identification and Characterization of Serum Biomarkers Associated with Breast Cancer Progression. Brigham Young University; 2016.
  • 2. World-Bank. List of Economies: Lower and Middle Income Countries. 2016.
  • 3. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol. 2008;9(8):730-56. doi: 10.1016/S1470-2045(08)70179-7. [PubMed: 18639491].
  • 4. Rahimzadeh M, Pourhoseingholi MA, Kavehie B. Survival Rates for Breast Cancer in Iranian Patients: a Meta- Analysis. Asian Pac J Cancer Prev. 2016;17(4):2223-7. [PubMed: 27221922].
  • 5. Geiger TR, Peeper DS. Metastasis mechanisms. Biochim Biophys Acta. 2009;1796(2):293-308. doi: 10.1016/j.bbcan.2009.07.006. [PubMed: 19683560].
  • 6. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet. 2007;369(9574):1742-57. doi: 10.1016/S0140-6736(07)60781-8. [PubMed: 17512859]. [PubMed Central: PMC2214903].
  • 7. Hashemi ZS, Khalili S, Forouzandeh Moghadam M, Sadroddiny E. Lung cancer and miRNAs: a possible remedy for anti-metastatic, therapeutic and diagnostic applications. Expert Rev Respir Med. 2017;11(2):147-57. doi: 10.1080/17476348.2017.1279403. [PubMed: 28118799].
  • 8. Nasiri M, Peeri M, Matinhomaei H. Endurance Training Attenuates Angiogenesis Following Breast Cancer by Regulation of MiR-126 and MiR-296 in Breast Cancer Bearing Mice. Int J Cancer Manag. 2017;10(6). doi: 10.5812/ijcm.8067.
  • 9. Hurst DR, Edmonds MD, Welch DR. Metastamir: the field of metastasis-regulatory microRNA is spreading. Cancer Res. 2009;69(19):7495-8. doi: 10.1158/0008-5472.CAN-09-2111. [PubMed: 19773429]. [PubMed Central: PMC2756311].
  • 10. Choghaei E, Khamisipour G, Falahati M, Naeimi B, Mossahebi-Mohammadi M, Tahmasebi R, et al. Knockdown of microRNA-29a Changes the Expression of Heat Shock Proteins in Breast Carcinoma MCF-7 Cells. Oncol Res. 2016;23(1-2):69-78. doi: 10.3727/096504015X14478843952906. [PubMed: 26802653].
  • 11. Hashemi ZS, Moghadam MF, Soleimani M. Comparison of TGFbR2 down-regulation in expanded HSCs on MBA/DBM scaffolds coated by UCB stromal cells. In Vitro Cell Dev Biol Anim. 2015;51(5):495-506. doi: 10.1007/s11626-014-9854-y. [PubMed: 25539863].
  • 12. Kumar S, Kumar A, Shah PP, Rai SN, Panguluri SK, Kakar SS. MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res. 2011;4(1):17. doi: 10.1186/1757-2215-4-17. [PubMed: 21939554]. [PubMed Central: PMC3205057].
  • 13. Mohammadpour H, Khalili S, Hashemi ZS. Kremen is beyond a subsidiary co-receptor of Wnt signaling: an in silico validation. Turk J Biol. 2015;39:501-10. doi: 10.3906/biy-1409-1.
  • 14. Wu K, Zhao Z, Ma J, Chen J, Peng J, Yang S, et al. Deregulation of miR-193b affects the growth of colon cancer cells via transforming growth factor-beta and regulation of the SMAD3 pathway. Oncol Lett. 2017;13(4):2557-62. doi: 10.3892/ol.2017.5763. [PubMed: 28454433]. [PubMed Central: PMC5403328].
  • 15. Tsai KW, Leung CM, Lo YH, Chen TW, Chan WC, Yu SY, et al. Arm Selection Preference of MicroRNA-193a Varies in Breast Cancer. Sci Rep. 2016;6:28176. doi: 10.1038/srep28176. [PubMed: 27307030]. [PubMed Central: PMC4910092].
  • 16. Mamoori AM, Wahab R, Islam F, Lee K, Smith RA, Gopalan V, et al., editors. Downregulation of miR-193a and its correlation with clinical and pathological behavior of colorectal cancer. AACR Annual Meeting. Washington, DC. American Association for Cancer Research (AACR); 2017.
  • 17. Li XF, Yan PJ, Shao ZM. Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer. Oncogene. 2009;28(44):3937-48. doi: 10.1038/onc.2009.245. [PubMed: 19701247].
  • 18. Leivonen SK, Makela R, Ostling P, Kohonen P, Haapa-Paananen S, Kleivi K, et al. Protein lysate microarray analysis to identify microRNAs regulating estrogen receptor signaling in breast cancer cell lines. Oncogene. 2009;28(44):3926-36. doi: 10.1038/onc.2009.241. [PubMed: 19684618].
  • 19. Bargaje R, Hariharan M, Scaria V, Pillai B. Consensus miRNA expression profiles derived from interplatform normalization of microarray data. RNA. 2010;16(1):16-25. doi: 10.1261/rna.1688110. [PubMed: 19948767]. [PubMed Central: PMC2802026].
  • 20. Chang KH, Mestdagh P, Vandesompele J, Kerin MJ, Miller N. MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. BMC Cancer. 2010;10:173. doi: 10.1186/1471-2407-10-173. [PubMed: 20429937]. [PubMed Central: PMC2873395].
  • 21. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA. 2008;14(5):844-52. doi: 10.1261/rna.939908. [PubMed: 18375788]. [PubMed Central: PMC2327352].
  • 22. Shokrollahi Barough M, Hasanzadeh H, Barati M, Pak F, Kokhaei P, Rezaei-Tavirani M. Apoptosis/Necrosis Induction by Ultraviolet, in ER Positive and ER Negative Breast Cancer Cell Lines. Iran J Cancer Prev. 2015;8(6). doi: 10.17795/ijcp-4193.
  • 23. Chatterjee S, Fasler M, Bussing I, Grosshans H. Target-mediated protection of endogenous microRNAs in C. elegans. Dev Cell. 2011;20(3):388-96. doi: 10.1016/j.devcel.2011.02.008. [PubMed: 21397849].
  • 24. Zheng L, Cai Y, Zhou L, Huang P, Ren X, Zuo A, et al. Benzoquinone from Fusarium pigment inhibits the proliferation of estrogen receptor-positive MCF-7 cells through the NF-kappaB pathway via estrogen receptor signaling. Int J Mol Med. 2017;39(1):39-46. doi: 10.3892/ijmm.2016.2811. [PubMed: 27878233]. [PubMed Central: PMC5179178].
  • 25. O'Day E, Lal A. MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res. 2010;12(2):201. doi: 10.1186/bcr2484. [PubMed: 20346098]. [PubMed Central: PMC2879559].
  • 26. Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 2010;32(1-2):35-48. doi: 10.3233/BD-2010-0307. [PubMed: 21778573]. [PubMed Central: PMC3532890].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments